Botulism MedWatch alert
Executive Summary
FDA issues a MedWatch alert due to reports of adverse events and death following the use of botulinum toxins Feb. 8. The early communication about an ongoing safety review of Allergan's Botox and Botox Cosmetic (type A) and Solstice Neurosciences' Myobloc (type B) cites adverse events for both FDA-approved and unapproved uses. The events are "suggestive of botulism," the alert states, and advises health care professionals to be alert for potency differences among botulinum products and signs and symptoms of systemic effects of treatment...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.